Market revenue in 2023 | USD 5,278.4 million |
Market revenue in 2030 | USD 12,677.4 million |
Growth rate | 13.3% (CAGR from 2023 to 2030) |
Largest segment | Circulating cell free dna (ccfdna) |
Fastest growing segment | Circulating Cell Free DNA (ccfDNA) |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Circulating Cell Free DNA (ccfDNA) |
Key market players worldwide | Qiagen NV, Charles River Laboratories International Inc, Roche Holding AG ADR, Thermo Fisher Scientific Inc, Eurofins Scientific SE, PerkinElmer, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Merck KGaA, Siemens Healthineers AG ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare biomarkers specimen collection and stabilization market will help companies and investors design strategic landscapes.
Circulating cell free dna (ccfdna) was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Asia Pacific rare biomarkers specimen collection and stabilization market based on circulating cell free dna (ccfdna) covering the revenue growth of each sub-segment from 2018 to 2030.
The ongoing conferences and seminars for raising awareness about the role of rare biomarkers in disease management, among Asian population including patients, healthcare personnel, and research entities, are driving the revenue share of this regional market.
For instance, in September 2019, a conference titled Circulating Biomarkers, Exosomes & Liquid Biopsy Asia 2019 was conducted in Seoul, Korea. In March 2019, Precipio, Inc., a specialty diagnostics company, announced the continuous purchase for its ICP liquid biopsy enrichment solution from both repeat and new customers in Japan.
Recently, the Tokyo-based Kyorin University Hospital placed its third order for ICP assay. This reflects the expanding liquid biopsy space in this region.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific rare biomarkers specimen collection and stabilization market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific rare biomarkers specimen collection and stabilization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account